Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 14/20 | 0.36 |
| ▸ | JAK2 | O60674 | 8/20 | 0.36 |
| ▸ | TYK2 | P29597 | 7/20 | 0.36 |
| ▸ | JAK3 | P52333 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4258112 | 0.88 | FFAR1 (0.39) | FFAR1SMN1; SMN2 | |
| SCHEMBL938503 | 0.83 | FFAR1 (0.54) | FFAR1JAK1JAK2TYK2JAK3 | |
| SCHEMBL13100015 | 0.80 | FFAR1 (0.43) | FFAR1 | |
| SCHEMBL11929413 | 0.80 | FFAR1 (0.36) | FFAR1 | |
| SCHEMBL13165395 | 0.80 | FFAR1 (0.32) | FFAR1 | |
| SCHEMBL10280187 | 0.80 | FFAR1 (0.38) | FFAR1 | |
| SCHEMBL13039625 | 0.79 | FFAR1 (0.33) | FFAR1 | |
| SCHEMBL12949820 | 0.78 | ALDH1A1 (0.36) | FFAR1JAK1JAK2TYK2JAK3 | |
| SCHEMBL10280195 | 0.77 | FFAR1 (0.43) | FFAR1JAK1JAK2TYK2JAK3 | |
| SCHEMBL9888234 | 0.75 | FFAR1 (0.39) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | AOC3, CBR3, IDH3B | FFAR1 2345/4885JAK1 393/4885JAK2 182/4885 |
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | PDK1, PDK2, PDK4 | FFAR1 1676/4885JAK1 212/4885JAK2 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.